Pyrazolam

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pyrazolam
Pyrazolam-skeletal.svg
Systematic (IUPAC) name
8-Bromo-1-methyl-6-(pyridin-2-yl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Clinical data
  • Legal
Oral, Sublingual, rectal
Pharmacokinetic data
Half-life 17 hours
Identifiers
39243-02-2
PubChem CID 12562545
ChemSpider 15417688
Chemical data
Formula C16H12BrN5
354.204 g/mol

Pyrazolam is a benzodiazepine derivative originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s,[1] and subsequently "rediscovered" and sold as a designer drug and research chemical starting in 2012.[2]

Pyrazolam has structural similarities to alprazolam[3] and bromazepam. Unlike other benzodiazepines pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine.[2][4] It is most selective for the α2 and α3 receptor subtypes.[5]

References[edit]

  1. ^ US 3954728, "Preparation of triazolo benzodiazepines and novel compounds" 
  2. ^ a b Moosmann, B.; Hutter, M.; Huppertz, L. M.; Ferlaino, S.; Redlingshöfer, L.; Auwärter, V. (2013). "Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine". Forensic Toxicology 31 (2): 263. doi:10.1007/s11419-013-0187-4.  edit
  3. ^ Hester Jr, J. B.; Rudzik, A. D.; Kamdar, B. V. (1971). "6-Phenyl-4H-s-triazolo[4,3-a][l,4]benzodiazepines Which Have Central Nervous System Depressant Activity". J. Med. Chem 14 (11): 1078–1081. PMID 5165540. 
  4. ^ Characterization of the designer benzodiazepines pyrazolam and flubromazepam and study on their detectability in human serum and urine samples, B. Moosmann, M. Hutter, L. M. Huppertz and V. Auwärter
  5. ^ Hester, J. B.; von Voigtlander, P. (1979). "6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity". Journal of Medicinal Chemistry 22 (11): 1390. doi:10.1021/jm00197a021.  edit